Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Unbalanced Wnt signalling in AD: a DNA methylation effect

eWAD

Growing evidence suggests that unbalanced Wnt signalling contributes to early stages of Alzheimer´s Disease (AD). mRNA levels of the Wnt antagonist Dikkoff1 (Dkk1) are increased in AD brains and by Amyloid-ß (Aß) in vitro. Importantly, suppression of Dkk1 activity protects synapses from Aß. Genome-Wide Association Studies also provide evidence for...

Funding Programme
Start Date
End Date
Total Funding
€ 183 455
European Countries Involved

Uncover mechanisms of unconventional secretion of tau using functional CRISPR screens - From basic discoveries to neurodegenerative disease therapeutics

SeCRT

Most of secreted proteins transit through the endoplasmic reticulum (ER) and the Golgi apparatus. However, eukaryotic cells secrete cytosolic proteins, which do not enter the ER. Proteins that use this “unconventional secretory pathway” include factors with critical functions and deregulation of their transport is associated to a wide range of...

Funding Programme
Start Date
End Date
Total Funding
€ 224 934
European Countries Involved

Uncovering molecular and cellular mechanisms of immune cell trafficking across the blood-CSF barrier in autoimmunity

CNS Hidden Door

Immune cells continuously traverse our body, crossing vascular and epithelial barriers; from lymphatic organs into the blood, and from the blood into various tissues for surveillance or to fight infection. However, the brain has long been considered an immune-privileged organ. Barriers protecting the brain against infection or harmful toxic agents...

Funding Programme
Start Date
End Date
Total Funding
€ 2 412 448
European Countries Involved

Understanding selective neuronal vulnerability in Alzheimer’s disease

NEVULA

The aim of this action is to understand the mechanisms behind the susceptibility of enthorinal cortex II (ECII) neurons to neurofibrillary tangle (NFT) formation in Alzheimer´s disease. To do so we will modulate the expression of the genes that according to NetWAS (Network-wide Association Study) are more directly involved in NFT formation in ECII...

Funding Programme
Start Date
End Date
Total Funding
€ 247 059
European Countries Involved

UNDERSTANDING THE CAUSES OF THE RNA GAIN OF FUNCTION DISEASES

RNA DISEASES

It is now increasingly clear that most of our genome is transcribed, but that only a small portion is associated with protein coding gene. Indeed, recent analysis indicate that long non-coding RNA outnumbered by five fold the coding RNA sequences. Despite this abundance, very little is known on the function of these long non-coding RNA. The aim of...

Funding Programme
Start Date
End Date
Total Funding
€ 1 499 920
European Countries Involved

Understanding the mechanisms of neuronal secretory autophagy

NEURO-SECRET

Neurons transmit information by connecting with other neurons over long distances through their dendrites and axons. Repeated stimulation places a high metabolic demand on these cells, leading to the accumulation of defective organelles and protein aggregates. To maintain protein homeostasis, neurons rely on constitutive autophagy to remove these...

Funding Programme
Start Date
End Date
Total Funding
€ 232 916
European Countries Involved

Understanding the molecular basis of protein folding disorders and protein quality control in muscle

MUSCLE-QC

Mutations in certain proteins can cause their misfolding and aggregation, posing a potential threat to the health of an organism. Protein aggregation is counteracted by protein quality control (PQC) mechanisms that reduce the amounts of damaged molecules. As we age, however, the crucial surveillance mechanisms weaken and become less effective...

Funding Programme
Start Date
End Date
Total Funding
€ 2 498 824
European Countries Involved

Unlocking cognition by Pulsatile GnRH in Alzheimer's DiseasE

UPGRADE

Cognitive decline associated with Alzheimer disease (AD) and other age-related dementias affects ~55 million people worldwide, and is a growing problem in aging European societies. However, most drugs fail at clinical trial, and approved treatments aimed at controlling or reversing pathological changes in the brain do not improve cognition in...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Unmasking cellular and molecular networks encoding risk and resilience in Alzheimer’s disease

AD_AGING_AND_GENDER

Alzheimer’s disease (AD) is a crucial problem in our society, raising the need for new therapeutic targets. Evidence suggests multiple non-neuronal cells are implicated in the systemic deficits of AD, but the complex cellular diversity in the brain hampers the investigation of specific cells and their interactions. Moreover, the course of the...

Funding Programme
Start Date
End Date
Total Funding
€ 1 500 000
European Countries Involved

Unraveling Bilobalide Biosynthesis for Sustainable and Scalable Production in Yeast

Biloba.bio

Ginkgo biloba extracts are among the most widely used plant-based health supplements in the United States and Europe. However, increasing demand has led to unsustainable overharvesting, resulting in Ginkgo biloba being classified as an endangered species. These extracts contain bioactive compounds, such as ginkgolides and bilobalide. Bilobalide, in...

Funding Programme
Start Date
End Date
Total Funding
€ 263 393
European Countries Involved

Unraveling the impact of pathological Tau phosphorylations on the early Tau interactome in Alzheimer's disease

Tau-Stick2Me

The Tau protein during Alzheimer's disease (AD) becomes hyperphosphorylated, misfolds, and aggregates into neurofibrillary tangles (NFTs). Despite knowing the involvement of Tau in AD, the exact mechanism that drives Tau-mediated toxicity is largely unclear. Studying the Tau interactome is an excellent way to decipher the mechanism of Tau toxicity...

Funding Programme
Start Date
End Date
Total Funding
€ 216 240
European Countries Involved

Unraveling the impact of RNA-editing in neurodegeneration: a focus on TDP-43 related frontotemporal dementia.

NeuroEDIT

Age-related neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD), are a major public health problem since there is no effective treatment due to the poor understanding of the pathological processes involved in neuronal death. RNA editing, particularly A-to-I changes mediated by ADAR enzymes...

Funding Programme
Start Date
End Date
Total Funding
€ 194 074
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).